Samsung Biologics Shares Decline on CHF 1.46 Billion Offer for PolyPeptide Group

Shares of Samsung Biologics (KS:207940) fell on Monday after the South Korean biopharmaceutical giant announced a significant all-cash offer to acquire Switzerland-based PolyPeptide Group AG (SIX:PPGN). The proposed deal, valued at approximately CHF 1.46 billion (Swiss francs), prompted a negative investor reaction to the substantial capital expenditure.

The Acquisition Offer

Samsung Biologics has offered to acquire 100% of PolyPeptide for CHF 44.31 per share. This price represents a premium of approximately 6% to PolyPeptide's closing price on Friday.

The company did not specify how it intends to fund the all-cash transaction, which is being described as one of the largest merger and acquisition deals in the history of South Korea's pharmaceutical and biotech sector. Following the news, Samsung Biologics' stock dropped 2.9% to trade at ₩1,355,000.

Strategic Rationale

The acquisition is a strategic move by Samsung Biologics to establish a significant presence in the rapidly expanding market for peptide active pharmaceutical ingredients (APIs). This segment is experiencing soaring demand driven by the popularity of GLP-1-based treatments for diabetes and obesity.

Ad

By acquiring PolyPeptide, Samsung Biologics gains immediate access to a well-established player with over 70 years of manufacturing expertise. PolyPeptide operates six manufacturing facilities across key global markets, including the United States, Belgium, France, Sweden, and India, providing Samsung Biologics with an instant operational foothold.

Broader Market Pressures

The decline in Samsung Biologics' shares also occurred amid a challenging broader market environment. South Korea's benchmark KOSPI index slid over 4% on Monday, continuing a period of high volatility that saw the index lose roughly 8.8% in the prior week.

A tighter domestic financial backdrop is also weighing on investor sentiment. The Bank of Korea recently raised its benchmark interest rate to 2.75%, its first hike in more than three years, increasing borrowing costs and adding pressure to capital-intensive growth stocks.